A. Dingemans

发表

Within-day variation of bioelectrical resistance measurements in patients with chronic obstructive pulmonary disease.

E. Wouters, A. Schols, P. Soeters, 1990, Clinical nutrition.

Immune checkpoint inhibitors versus second line chemotherapy for patients with lung cancer refractory to first line chemotherapy.

J. Mazières, B. Besse, L. Mezquita, 2020, Respiratory medicine and research.

Clinical resistance to topoisomerase-targeted drugs.

G. Giaccone, H. Pinedo, A. Dingemans, 1998, Biochimica et biophysica acta.

Topoisomerase IIα and other drug resistance markers in advanced non-small cell lung cancer

G. Giaccone, G. Scagliotti, P. Postmus, 2001 .

Expression of DNA topoisomerase IIalpha and topoisomerase IIbeta genes predicts survival and response to chemotherapy in patients with small cell lung cancer.

G. Giaccone, P. Postmus, A. Dingemans, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of ≥1% by the USA Food and Drug Administration.

S. Novello, J. Vansteenkiste, T. Čufer, 2019 .

Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small cell lung cancer with a PD-L1 expression level of ≥ 1% by the U.S. Food and Drug Administration.

S. Novello, J. Vansteenkiste, T. Čufer, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Prevalence and characteristics of nutritional depletion in patients with stable COPD eligible for pulmonary rehabilitation.

E. Wouters, A. Schols, P. Soeters, 1993, The American review of respiratory disease.

Detection of cytokeratin-19 transcripts by reverse transcriptase-polymerase chain reaction in lung cancer cell lines and blood of lung cancer patients.

G. Giaccone, P. Postmus, R. Brakenhoff, 1997, Laboratory investigation; a journal of technical methods and pathology.

ESMO expert consensus statements on the management of EGFR mutant Non-Small Cell Lung Cancer.

P. Jänne, I. Wistuba, L. Sequist, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Expression of the human major vault protein LRP in human lung cancer samples and normal lung tissues.

G. Giaccone, P. Postmus, R. Scheper, 1996, Annals of Oncology.

Redo pull-through surgery in Hirschsprung disease: Short-term clinical outcome.

I. de Blaauw, A. Dingemans, R. Rassouli-Kirchmeier, 2017, Journal of pediatric surgery.

LBA85 REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancer

L. Livi, M. Mauer, T. Berghmans, 2020 .

Immune checkpoint inhibitors in non-small-cell lung cancer: key to long-term survival?

A. Dingemans, Lel Hendriks, 2019, The Lancet. Respiratory medicine.

Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial.

R. Dziadziuszko, J. Mazières, P. Garrido, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer.

G. Giaccone, P. Postmus, J. V. van Mourik, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

P1.28-08 Definition of Resectable Stage III Non-Small Cell Lung Cancer: A Systematic Review from EORTC Lung Cancer Group

A. Dingemans, C. Faivre-Finn, T. Berghmans, 2023, Journal of Thoracic Oncology.

OA06.05 Consensual Definition of Stage III NSCLC Resectability: EORTC-Lung Cancer Group Initiative with Other Scientific Societies

A. Dingemans, C. Faivre-Finn, M. Guckenberger, 2023, Journal of Thoracic Oncology.